sure, we have had discussions on this - many many times. + another poster (danhoff) has posted a lot of potential calc around revenue vs EPS vs EBTIDA etc....acres and acres of it + we have current Canaccord broker estimates (only analyst covering AT1 so far)
Summarising:
- ~60% avg margin (quoted by CEO several times + in the FY20 doc)
- assumption though is margin will keep evolving as its based for now on mainly C-19 OEM supply avg (largest FY20 segment). We have that Ab test revenue % sharing deal with AccBio (yet to kick off) + a longer term supply agreement with NGBio (also pending), which might change this avg significantly for C-19 market.
- then we have the core HIV biz of course, which is AT1's own tests (so should be higher margin than just device supply/sales?) and then we have the added AccBio Ag test sales (maybe) to increase C-19 revenue further.
- anyway, using the FY20 qty sales VS rev data, estimate per device revenue:
Covid Ab (primarily NGBio) $3.4m for 1.08m $3.148 HIV (all) $1.2m for 226k $5.310 OEM (all except Covid19) $0.8m for 266k $3.008
- Below are the latest production scale-up numbers (Nov'20 AGM doc).
As we only have the FY20 numbers above + only the minimum C-19 order qty agreements (most of which yet to generate any measurable rev trend) + only Q1 data (which wasn't broken down) = we don't know how much production capacity is being allocated for which segment revenue.
You could certainly mix all of the above and end up with a simple Avg Revenue Per Device guesstimate....
Anyway, best assumption revenue (which we have been working around + using similar broker data). See danhoff's recent posts today for moire detail
- FY21 ($20m+) / FY22 ($40m+) / FY23 ($60m+)
But, as I posted on the Qtrly thread today to danhoff's most recent calc...these are all assumption darts into the distant horizon...I feel we don't have enough test segment data or order-sale trends to hang our collective handbags on yet..
Feel free to calc and post your thoughts, if you see different stuff in the docs + data....
- Forums
- ASX - By Stock
- AT1
- AT1 FY21 - General Discussion + FA
AT1 FY21 - General Discussion + FA, page-282
-
-
- There are more pages in this discussion • 2,152 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AT1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.0¢ |
Change
0.001(2.63%) |
Mkt cap ! $12.46M |
Open | High | Low | Value | Volume |
2.0¢ | 2.0¢ | 2.0¢ | $101 | 5.197K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 816162 | 1.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.0¢ | 426397 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 816162 | 0.019 |
5 | 656664 | 0.018 |
1 | 60000 | 0.016 |
3 | 366662 | 0.015 |
1 | 36000 | 0.014 |
Price($) | Vol. | No. |
---|---|---|
0.020 | 426397 | 4 |
0.021 | 32000 | 1 |
0.022 | 40000 | 1 |
0.024 | 126743 | 3 |
0.025 | 459000 | 2 |
Last trade - 15.59pm 18/09/2024 (20 minute delay) ? |
Featured News
AT1 (ASX) Chart |